LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

Search

TransMedics Group Inc

Затворен

СекторЗдравеопазване

73.67 -2.19

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

72.59

Максимум

75.5

Ключови измерители

By Trading Economics

Приходи

-98M

7.3M

Продажби

13M

174M

P/E

Средно за сектора

17.272

49.712

EPS

0.3

Марж на печалбата

4.206

Служители

898

EBITDA

-4.9M

28M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+59.25% upside

Дивиденти

By Acuity

Следващи печалби

29.07.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-745M

2.6B

Предишно отваряне

75.86

Предишно затваряне

73.67

Настроения в новините

By Acuity

50%

50%

128 / 342 Класиране в Healthcare

TransMedics Group Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Относно TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat